HANSA BIOPHARMA Aktie

 

LUND, Sweden, March 26, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (NASDAQ STOCKHOLM: HNSA), today published its Annual and Sustainability Reports for 2025. Peter Nicklin, Chair of the Board, Hansa Biopharma, said: "2025 was a year of transformation for Hansa......

Lund, Sweden, March 20, 2026. Hansa Biopharma AB (publ) (Nasdaq Stockholm: HNSA) (“Hansa” or the “Company”) today announces that it has entered into a U.S. convertible note purchase agreement with certain funds managed by Athyrium Capital Management (“Athyrium”), comprising USD 30 million aggregate principal amount of unsecured convertible senior notes (the “Financing”). The Financing extends the Company's runway into mid 2027 and ensures a robust launch of imlifidase in the US, subject to approval. The Financing consists of unsecured convertible senior notes with an aggregate principal...

Lund, Sweden, 13 March, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will be presenting at Redeye Theme Event: Commercialization in Life Science in Stockholm, at 10:15 AM CET on Friday 20 March, 2026. Hansa Biopharma VP Global Corporate Affairs Kerstin Falck will also be attending the event. If you are interested in meeting with Hansa's management, please contact Hansa Biopharma at ir@hansabiopharma.com. Event: Redeye Theme Event: Commercialization in Life Science, Hansa Biopharma Corporate...

Lund, Sweden, 10 March, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will participate in a fireside chat at DNB Carnegie Healthcare Conference 2026 in Stockholm, at 15:10 PM EDT on Thursday 12 March, 2026. Hansa Biopharma VP Global Corporate Affairs Kerstin Falck will also be attending the event. If you are interested in meeting with Hansa's management, please contact Hansa Biopharma at ir@hansabiopharma.com. Event: DNB Carnegie Healthcare Conference 2026, Hansa Biopharma Fireside Chat Date, Time, and...

Lund, Sweden, 9 March, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will be participating in a panel discussion titled “The Path to Public: Mastering Your Exit Strategy” at LSX Investival Showcase USA in Miami, at 15:15 PM EDT on Tuesday 10 March, 2026. Hansa Biopharma COO and President U.S. Maria Törnsén, and CMO Richard Philipson will also be attending the event. If you are interested in meeting with Hansa's management, please contact Hansa Biopharma at ir@hansabiopharma.com. Event: Panel Discussion at...

Lund, Sweden, 6 March, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will participate in a fireside chat at Leerink Global Healthcare Conference in Miami, at 13:40 PM EDT on Monday 9 March, 2026. Hansa Biopharma COO and President U.S. Maria Törnsén, and CMO Richard Philipson will also be attending the event. If you are interested in meeting with Hansa's management, please contact Hansa Biopharma at ir@hansabiopharma.com. Event: Leerink Global Healthcare Conference, Hansa Biopharma Fireside Chat Date,...

If approved, imlifidase will be the first treatment to address highly sensitized patients awaiting kidney transplantation. LUND, Sweden, March 4, 2026 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced that the Food and Drug......

Lund, Sweden, 23 February, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will be presenting at TD Cowen's 46th Annual Health Care Conference in Boston, at 11:10-11:40 AM EST on Monday 2 March, 2026. Hansa Biopharma CFO Evan Ballantyne, and COO and President U.S. Maria Törnsén, will also be attending the event. If you are interested in meeting with Hansa's management, please contact Hansa Biopharma at ir@hansabiopharma.com. Event: TD Cowen 46th Annual Health Care Conference, Hansa Biopharma Corporate...

LUND, Sweden, Feb. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced that its Biologics License Application (BLA) for imlifidase has been accepted by the U.S. Food and Drug Administration (FDA). FDA's filing review was......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Strong Q4 with 76.0 MSEK in revenue, up 135% from Q4 2024. Submission of Biologics License Application (BLA) for imlifidase for highly sensitized patients awaiting kidney transplantation. Successfully completed a directed share issue raising 671.5 MSEK (~ $71.3M). LUND, Sweden, Feb. 11,......

Lund, Sweden, 26 January, 2026. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), will publish its year-end report for January - December 2025 on Wednesday 11 February, 2026. Interested parties may join the Company's quarterly conference call on the same date at 14:00 CET / 8:00 AM EST. The event will be hosted by Renée Aguiar-Lucander, CEO, Evan Ballantyne, CFO, Richard Philipson, CMO, and Maria Törnsén, COO and President U.S. During the call, management will review the Company's year-end financial results and provide a business and pipeline update. The presentation will be held in...

LUND, Sweden, Jan. 22, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the company has been awarded the prestigious 2025 SwedenBIO Award. The award was presented at the SwedenBIO Summit in Stockholm on 21 January, where Hansa was selected as......

The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patients Imlifidase is an enzyme that rapidly and efficiently cleaves all types of immunoglobulin G (IgG) antibodies both intra- and extra-vascularly to inhibit IgG-mediated......

The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patients Imlifidase is an enzyme that rapidly and efficiently cleaves all types of immunoglobulin G (IgG) antibodies both intra- and extra-vascularly to inhibit IgG-mediated......

Lund, Sweden,19 December 19, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Hansa CEO Renée Aguiar-Lucander will be presenting at J.P. Morgan's 44[th] Annual Healthcare Conference at 10:30 AM PST, Georgian, Weston St. Francis, in San Francisco, California. The conference runs from Monday 12 January to Thursday 15 January and will also be attended by CFO Evan Ballantyne, COO Maria Törnsén, CMO Richard Philipson and CLO Brain Gorman. The J.P. Morgan Healthcare Conference is a major healthcare investment symposium in the industry, which connects global...

Lund, Sweden, 16 December 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that GOOD-IDES-02, a global pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease, did not meet its primary endpoint. The endpoint was renal function at 6 months, evaluated by estimated glomerular filtration rate (eGFR). Approximately 60% of patients treated with imlifidase followed by the standard of care (SoC) protocol defined in the trial did not require dialysis at 6 months, which represented a substantial improvement and clinical benefit compared to what has...

Lund, Sweden, December 15, 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced a reorganization of its European and International Commercial and Medical Affairs operations, effective December 11, 2025. This action follows a comprehensive review of the European commercial operations over the past months, as referenced in the CEO letter of the Q3 Jan–Sept interim report. The review identified key areas for improvement and investment aimed at addressing recent challenges and enhancing performance and predictability in 2026. New Leadership Appointment As part of...

Lund, Sweden, 13 November, 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will be participating in a fireside chat with Farzin Haque, Biotechnology Equity Research Analyst, Jefferies, at the Jefferies Healthcare Conference in London, on Monday 17 November, 2025. Aguiar-Lucander will also present Hansa Biopharma at DNB Carnegie's 16[th] Annual Nordic Healthcare Conference in Oslo, Tuesday 25 November, 2025. If you are interested in meeting with Hansa's management, please contact Hansa Biopharma at ir@...

Lund, Sweden, 12 November 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today will host a virtual event featuring two distinguished transplant surgeons; Professor Robert Montgomery from NYU Langone Transplant Institute and Professor Matthew Cooper from the Medical College of Wisconsin, to provide deeper insights into the medical journey of highly sensitized patients awaiting a kidney transplant and share perspectives on the clinical relevance of the topline results from the US Phase 3 ConfIdeS study.  The event will take place today, Wednesday 12 November, 2025, at  9:00 AM EST...